{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:40Z","timestamp":1787841520074,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01869-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:58:27Z","timestamp":1781283507000},"page":"1014-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in CD8-positive lymphocytes following chemotherapy with concomitant bevacizumab in HER2-negative breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Eriko","family":"Narusawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Koibuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Kanno Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-5466","authenticated-orcid":false,"given":"Sasagu","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1869_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/s0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"1920","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 1920;365:1687\u2013717. https:\/\/doi.org\/10.1016\/s0140-6736(05)66544-0.","journal-title":"Lancet"},{"key":"1869_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/15680096113139990074","volume":"13","author":"VP Chekhonin","year":"2013","unstructured":"Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets. 2013;13:423\u201343. https:\/\/doi.org\/10.2174\/15680096113139990074.","journal-title":"Curr Cancer Drug Targets"},{"key":"1869_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841\u20134. https:\/\/doi.org\/10.1038\/362841a0.","journal-title":"Nature"},{"key":"1869_CR4","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1200\/jco.2008.21.6630","volume":"27","author":"R Gray","year":"2009","unstructured":"Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966\u201372. https:\/\/doi.org\/10.1200\/jco.2008.21.6630.","journal-title":"J Clin Oncol"},{"key":"1869_CR5","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/nejmoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376. https:\/\/doi.org\/10.1056\/nejmoa072113.","journal-title":"N Engl J Med"},{"key":"1869_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"key":"1869_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00795-017-0170-y","volume":"50","author":"S Kurozumi","year":"2017","unstructured":"Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, et al. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol. 2017;50:185\u201394. https:\/\/doi.org\/10.1007\/s00795-017-0170-y.","journal-title":"Med Mol Morphol"},{"key":"1869_CR8","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"key":"1869_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12885-015-1641-y","volume":"15","author":"S Kurozumi","year":"2015","unstructured":"Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer. 2015;15:622. https:\/\/doi.org\/10.1186\/s12885-015-1641-y.","journal-title":"BMC Cancer"},{"key":"1869_CR10","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/jco.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672\u201385. https:\/\/doi.org\/10.1200\/jco.1998.16.8.2672.","journal-title":"J Clin Oncol"},{"key":"1869_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2014","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014;26:259\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdu450.","journal-title":"Ann Oncol"},{"key":"1869_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00795-024-00386-z","volume":"57","author":"E Narusawa","year":"2024","unstructured":"Narusawa E, Kurozumi S, Katayama A, Koibuchi Y, Ogawa A, Takata D, et al. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer. Med Mol Morphol. 2024;57:177\u201384. https:\/\/doi.org\/10.1007\/s00795-024-00386-z.","journal-title":"Med Mol Morphol"},{"key":"1869_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41598-018-38272-1","volume":"9","author":"S Kurozumi","year":"2019","unstructured":"Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, et al. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep. 2019;9:1583. https:\/\/doi.org\/10.1038\/s41598-018-38272-1.","journal-title":"Sci Rep"},{"key":"1869_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13058-015-0632-x","volume":"17","author":"M Miyashita","year":"2015","unstructured":"Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, et al. Prognostic significance of tumor-infiltrating CD8\u2009+\u2009and FOXP3\u2009+\u2009lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015;17:124. https:\/\/doi.org\/10.1186\/s13058-015-0632-x.","journal-title":"Breast Cancer Res"},{"key":"1869_CR15","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"key":"1869_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.21873\/invivo.12082","volume":"34","author":"T Fujii","year":"2020","unstructured":"Fujii T, Hirakata T, Kurozumi S, Tokuda S, Nakazawa Y, Obayashi S, et al. VEGF-A is associated with the degree of TILs and PD-L1 expression in primary breast cancer. Vivo. 2020;34:2641\u20136.","journal-title":"Vivo"},{"key":"1869_CR17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4 H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078. https:\/\/doi.org\/10.3389\/fimmu.2019.01078.","journal-title":"Front Immunol"},{"key":"1869_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.5-2004-37","volume":"5","author":"G Gasparini","year":"2000","unstructured":"Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5:37\u201344. https:\/\/doi.org\/10.1634\/theoncologist.5-2004-37.","journal-title":"Oncologist"},{"key":"1869_CR19","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3389\/fimmu.2018.03081","volume":"9","author":"M Georganaki","year":"2018","unstructured":"Georganaki M, van Hooren L, Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol. 2018;9:3081. https:\/\/doi.org\/10.3389\/fimmu.2018.03081.","journal-title":"Front Immunol"},{"key":"1869_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/annonc\/mdv241","volume":"26","author":"MV Dieci","year":"2014","unstructured":"Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;26:1518. https:\/\/doi.org\/10.1093\/annonc\/mdv241.","journal-title":"Ann Oncol"},{"key":"1869_CR21","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig A-M, Kaech SM, Wherry EJ. CD8\u2009+\u2009T cells in the cancer-immunity cycle. Immunity. 2023;56:2231\u201353. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.005.","journal-title":"Immunity"},{"key":"1869_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","volume":"35","author":"A Schietinger","year":"2013","unstructured":"Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2013;35:51\u201360. https:\/\/doi.org\/10.1016\/j.it.2013.10.001.","journal-title":"Trends Immunol"},{"key":"1869_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1869_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/nejmoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326. https:\/\/doi.org\/10.1056\/nejmoa2202809.","journal-title":"N Engl J Med"},{"key":"1869_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang C-W, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol. 2019;5:334. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5152.","journal-title":"JAMA Oncol"},{"key":"1869_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/nejmoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/nejmoa1910549.","journal-title":"N Engl J Med"},{"key":"1869_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/nejmoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/nejmoa1915745.","journal-title":"N Engl J Med"},{"key":"1869_CR28","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/nejmoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/nejmoa1716948.","journal-title":"N Engl J Med"},{"key":"1869_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","volume":"171","author":"Y Ozaki","year":"2022","unstructured":"Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (WJOG9917B). Eur J Cancer. 2022;171:193\u2013202. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.014.","journal-title":"Eur J Cancer"},{"key":"1869_CR30","doi-asserted-by":"publisher","first-page":"PS4","DOI":"10.1158\/1538-7445.sabcs20-ps4-14","volume":"81","author":"Y Ozaki","year":"2021","unstructured":"Ozaki Y, Kitano S, Tsurutani J, Iwasa T, Takahashi M, Mukohara T, et al. Abstract PS4-14: immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR). Cancer Res. 2021;81:PS4\u201314. https:\/\/doi.org\/10.1158\/1538-7445.sabcs20-ps4-14.","journal-title":"Cancer Res"},{"key":"1869_CR31","unstructured":"Japan Registry of Clinical Trials (jRCT). (2024). Randomized phase II trial evaluating the efficacy of paclitaxel+bevacizumab induction followed by at Ezolizumab\u2009+\u2009nab-paclitaxel for PD-L1-positive metastatic triple negative breast cancer (JBCRG-M10,CMA-0196) (INDUCE trial). Identifier: jRCTs041240039. https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs041240039"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01869-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:14Z","timestamp":1787839154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01869-w","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK has received honoraria from Kyowa Kirin Co., Ltd, Daiichi Sankyo Co., Ltd, Taiho Pharmaceutical Co., Ltd, Eli Lilly and Company, MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical, Ltd., Dinow, Inc., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. No conflicts of interest have been reported for any of the other authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by National Hospital Organization Takasaki General Medical Center (reference no. 2021-53). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}}]}}